Pharmacy Articles

Pharmacy

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Ilic I et al. - In a trial to determine the influence of germinal-center B-cell (GCB) and non-GCB phenotypes of diffuse large B-cell lymphoma (DLBCL) on outcome of 92 pts treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP-like chemotherapy, with or without rituximab, it was shown that pts with immunohistochemically determined GCB-type DLBCL did not have an improved prognosis, irrespective of whether they had received rituximab or not.

Methods

Results